STOCK TITAN
The best stock market news and trading tools all in one place—your must-have platform for investing success.
A must-have platform for stock market information, offering the best tools and updates to supercharge your trading.
Your trusted source for the best stock market news, trading tools, and expert advice. Everything traders need, in one place.

CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Corbus Pharmaceuticals (CRBP) announced the adjournment of its 2021 Annual Meeting to allow stockholders more time to vote on proposals, particularly Proposal 4, which seeks to double the authorized common stock from 150 million to 300 million shares. Currently, about 85% of votes cast support this proposal, but it requires a majority of outstanding shares for approval. The meeting will reconvene on June 17, 2021, at 9:00 a.m. ET. Corbus focuses on innovative medicines targeting the endocannabinoid system, with its lead candidate, lenabasum, currently being evaluated for chronic inflammatory diseases.

Positive
  • Proposal 4 has about 85% support among the votes cast.
  • The adjournment allows for further stockholder engagement on important matters.
Negative
  • Proposal 4 has not yet received a majority of outstanding shares, delaying potential financial strategies.

Norwood, MA, May 19, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it has adjourned its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) in order to provide stockholders additional time within which to vote on all proposals, including Proposal 4 to approve an amendment to the Company’s certificate of incorporation to increase the Company’s authorized shares of common stock from 150,000,000 to 300,000,000.

The Company believes there is significant support for Proposal 4. At the time of the Annual Meeting, approximately 85% of the votes cast on Proposal 4 were voted in favor of its approval. Because Proposal 4 must be approved by a majority of the outstanding shares of common stock, however, it has not yet received a sufficient number of votes in its favor. Because Corbus’ Board of Directors continues to believe that Proposal 4 is advisable and in the best interests of the Company’s stockholders to consider and act upon Proposal 4, the Company adjourned the Annual Meeting.

The adjourned meeting will be held at 9:00 a.m. ET on Thursday, June 17, 2021 at the following url: www.viewproxy.com/corbuspharma/2021/vm. The record date for the annual meeting is March 31, 2021.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to immunosuppressive medications in the treatment of chronic inflammatory and fibrotic diseases. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform.

Lenabasum is not approved for the treatment of any indication. For more information on Corbus’ clinical programs, please visit here.

For more information, visit http://www.corbuspharma.com/, and connect with us on TwitterLinkedIn, and Facebook.

Corbus Pharmaceuticals Contacts:

Ted Jenkins, Senior Director, Investor Relations and Corporate Communications
Phone: +1 (617) 415-7745
Email: ir@corbuspharma.com

Lindsey Smith, Director, Investor Relations and Corporate Communications
Phone: +1 (617) 415-7749
Email: mediainfo@corbuspharma.com


FAQ

What is the purpose of Corbus Pharmaceuticals' adjourned Annual Meeting on June 17, 2021?

The adjourned Annual Meeting aims to provide stockholders more time to vote on proposals, especially Proposal 4, which seeks to increase authorized shares.

What is Proposal 4 regarding Corbus Pharmaceuticals?

Proposal 4 seeks to increase the authorized shares of common stock from 150 million to 300 million.

What percentage of votes support Proposal 4 by Corbus Pharmaceuticals?

Approximately 85% of the votes cast on Proposal 4 are in favor of its approval.

Why was the 2021 Annual Meeting for Corbus Pharmaceuticals adjourned?

The meeting was adjourned to allow stockholders additional time to vote on all proposals, including Proposal 4.

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

CRBP Rankings

CRBP Latest News

CRBP Stock Data

214.85M
11.18M
0.75%
106.74%
19.75%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NORWOOD